NCT07015983: An ongoing trial by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
This trial is ongoing. It must report results 3 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07015983 |
|---|---|
| Title | A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 14, 2025 |
| Completion date | May 17, 2028 |
| Required reporting date | May 17, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 28, 2025 |
| Days late | None |